Group One Trading’s Quince Therapeutics QNCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$636K Buy
31,346
+31,277
+45,329% +$6.28M ﹤0.01% 3118
2025
Q4
$46.2K Buy
69
+19
+38% +$9.56K ﹤0.01% 5666
2025
Q3
$16.3K Sell
50
-31
-38% -$10.3K ﹤0.01% 6851
2025
Q2
$26.7K Sell
81
-7
-8% -$1.6K ﹤0.01% 6076
2025
Q1
$23.3K Sell
88
-101
-53% -$30.8K ﹤0.01% 5714
2024
Q4
$70.5K Buy
+189
New +$56.8K ﹤0.01% 4807
2023
Q4
Sell
-223
Closed -$49.8K 8048
2023
Q3
$49.8K Sell
223
-16
-7% -$4.18K ﹤0.01% 5101
2023
Q2
$71.7K Sell
239
-28
-10% -$8.72K ﹤0.01% 4950
2023
Q1
$83.1K Buy
267
+144
+117% +$28.2K ﹤0.01% 4455
2022
Q4
$15.6K Sell
123
-1
-0.8% -$167 ﹤0.01% 5759
2022
Q3
$33K Sell
124
-14
-10% -$5.33K ﹤0.01% 5733
2022
Q2
$61K Sell
138
-617
-82% -$436K ﹤0.01% 5405
2022
Q1
$934K Sell
755
-2,707
-78% -$3.68M ﹤0.01% 3156
2021
Q4
$8.74M Buy
3,462
+3,031
+703% +$18.5M 0.01% 1210
2021
Q3
$7.89M Buy
431
+309
+253% +$4.91M 0.01% 1273
2021
Q2
$1.29M Buy
122
+27
+28% +$226K ﹤0.01% 3116
2021
Q1
$685K Buy
95
+89
+1,483% +$640K ﹤0.01% 3669
2020
Q4
$33K Buy
6
+5
+500% +$44.3K ﹤0.01% 5250
2020
Q3
$5K Buy
+1
New +$9.1K ﹤0.01% 5648

Other funds holding QNCX

Group One Trading's QNCX Position: Q1 2026 in Review

Group One Trading sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 702 shares — an estimated $141K sold.

Group One Trading first reported a position in QNCX in Q4 2020 and held it in 11 quarters. The position peaked at $647K in Q1 2022. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Group One Trading reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 702 Quince Therapeutics shares in Q1 2026, an estimated $141K.
  • Group One Trading first reported a position in Quince Therapeutics in Q4 2020 and held it in 11 quarters.
  • Group One Trading's Quince Therapeutics position peaked at $647K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.